Neurocrine Biosciences (NASDAQ:

) shares moved up 76.95% to $17.27. The volume of Neurocrine Biosciences shares traded was 4406% higher than normal. Neurocrine Biosciences reported positive results of VMAT2 inhibitor NBI-98854 in Kinect 2 study. Epizyme (NASDAQ:

) shares rose 66.84% to $34.20. The volume of Epizyme shares traded was 1683% higher than normal. Epizyme reported two major milestone achievements. It announced the achievement of a proof of concept milestone in the EPZ-5676 DOT1L inhibitor clinical program. ANI Pharmaceuticals (NASDAQ:

) shares climbed 9.42% to $20.79. The volume of ANI Pharmaceuticals shares traded was 651% higher than normal. ANI Pharmaceuticals shares have jumped 121.45% over the past 52 weeks, while the S&P 500 index has surged 25.37% in the same period. Cray (NASDAQ:

) surged 14.40% to $31.07. The volume of Cray shares traded was 649% higher than normal. Cray affirmed its revenue outlook for 2013 and 2014.